Cost-Effectiveness of a Central Venous Catheter Care Bundle

被引:42
作者
Halton, Kate A. [1 ,2 ]
Cook, David [3 ]
Paterson, David L. [1 ,4 ]
Safdar, Nasia [5 ]
Graves, Nicholas [1 ,2 ]
机构
[1] Ctr Healthcare Related Infect Surveillance & Prev, Brisbane, Qld, Australia
[2] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia
[3] Princess Alexandra Hosp, Intens Care Unit, Brisbane, Qld 4102, Australia
[4] Univ Queensland, Clin Res Ctr, Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
[5] Univ Wisconsin, Dept Med, Infect Dis Sect, Sch Med & Publ Hlth, Madison, WI USA
来源
PLOS ONE | 2010年 / 5卷 / 09期
基金
英国医学研究理事会;
关键词
BLOOD-STREAM INFECTIONS; QUALITY-OF-LIFE; AUSTRALIA; ECONOMICS;
D O I
10.1371/journal.pone.0012815
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: A bundled approach to central venous catheter care is currently being promoted as an effective way of preventing catheter-related bloodstream infection (CR-BSI). Consumables used in the bundled approach are relatively inexpensive which may lead to the conclusion that the bundle is cost-effective. However, this fails to consider the nontrivial costs of the monitoring and education activities required to implement the bundle, or that alternative strategies are available to prevent CR-BSI. We evaluated the cost-effectiveness of a bundle to prevent CR-BSI in Australian intensive care patients. Methods and Findings: A Markov decision model was used to evaluate the cost-effectiveness of the bundle relative to remaining with current practice (a non-bundled approach to catheter care and uncoated catheters), or use of antimicrobial catheters. We assumed the bundle reduced relative risk of CR-BSI to 0.34. Given uncertainty about the cost of the bundle, threshold analyses were used to determine the maximum cost at which the bundle remained cost-effective relative to the other approaches to infection control. Sensitivity analyses explored how this threshold alters under different assumptions about the economic value placed on bed-days and health benefits gained by preventing infection. If clinicians are prepared to use antimicrobial catheters, the bundle is cost-effective if national 18-month implementation costs are below $1.1 million. If antimicrobial catheters are not an option the bundle must cost less than $4.3 million. If decision makers are only interested in obtaining cash-savings for the unit, and place no economic value on either the bed-days or the health benefits gained through preventing infection, these cost thresholds are reduced by two-thirds. Conclusions: A catheter care bundle has the potential to be cost-effective in the Australian intensive care setting. Rather than anticipating cash-savings from this intervention, decision makers must be prepared to invest resources in infection control to see efficiency improvements.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 45 条
  • [1] Effectiveness of bundled behavioural interventions to control healthcare-associated infections: a systematic review of the literature
    Aboelela, S. W.
    Stone, P. W.
    Larson, E. L.
    [J]. JOURNAL OF HOSPITAL INFECTION, 2007, 66 (02) : 101 - 108
  • [2] [Anonymous], 1996, COST EFFECTIVENESS H, DOI DOI 10.1093/OSO/9780195108248.001.0001
  • [3] *AUST I HLTH WELF, 2006, AUST HLTH 2006
  • [4] Eliminating catheter-related bloodstream infections in the intensive care unit
    Berenholtz, SM
    Pronovost, PJ
    Lipsett, PA
    Hobson, D
    Earsing, K
    Farley, JE
    Milanovich, S
    Garrett-Mayer, E
    Winters, BD
    Rubin, HR
    Dorman, T
    Perl, TM
    [J]. CRITICAL CARE MEDICINE, 2004, 32 (10) : 2014 - 2020
  • [5] The 100 000 Lives Campaign - Setting a goal and a deadline for improving health care quality
    Berwick, DM
    Calkins, DR
    McCannon, CJ
    Hackbarth, AD
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (03): : 324 - 327
  • [6] Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections
    Blot, SI
    Depuydt, P
    Annemans, L
    Benoit, D
    Hoste, E
    de Waele, JJ
    Decruyenaere, J
    Vogelaers, D
    Colardyn, F
    Vandewoude, KH
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 (11) : 1591 - 1598
  • [7] Bolz K, 2008, HEALTHC INFECT, V13, P48
  • [8] *BUR LAB STAT, BUR LAB STAT CONS PR
  • [9] Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1
  • [10] Cooper Nicola, 2005, J Health Serv Res Policy, V10, P245, DOI 10.1258/135581905774414187